ROS1 and non-small cell lung carcinoma: Numerous studies indicate that patients with NSCLC harboring ROS1 fusions exhibit high sensitivity to ROS1 tyrosine kinase inhibitors (ROS-TKIs) (Shaw et al., 2019; Shaw et al., 2017; Malik et al., 2014), leading to their incorporation into clinical guidelines as standard first-line therapies for this patient population.